Edmonds M. A renaissance in diabetic foot care: new evidence-based treatments. Lancet Diabetes Endocrinol. 2018 Nov;6(11):837-838.
http://pubmed.ncbi.nlm.nih.gov/30243804/
Game F, Jeffcoate W, Tarnow L, Jacobsen JL, Whitham DJ, Harrison EF, Ellender SJ, Fitzsimmons D, Löndahl M; LeucoPatch II trial team. LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial Lancet Diabetes Endocrinol. 2018 Nov;6(11):870-878.
https://pubmed.ncbi.nlm.nih.gov/30243803/
Edmonds M, Lázaro-Martinez JL, Alfayate-Garcîa JM, Martini J, Petit JM, Rayman G, Lobmann R, Uccioli L, Sauvadet A, Bohbot S, Kerihuel JC, Piagessi A. Sucrose octasulfate dressing versus controlled dressing in patients with neuroischaemic diabetic foot ulcers (EXPLORER): an international, multi-centre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2018; 6: 186-196.
https://pubmed.ncbi.nlm.nih.gov/29275068/
By the end of this module, you will be able to:
✓ Interpret research studies investigating new medications and approaches to infection, including hyperbaric oxygen therapy to treat diabetic foot disease
✓ Explain how SMART technology and advanced temperature monitoring can be used to identify, monitor, support and assess the effectiveness of timely interventions in people with diabetic foot disease
✓ Develop monitoring, assessment and treatment plans for people with diabetic foot disease
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.